Hemogram as marker of in-hospital mortality in COVID-19

Alejandro López-Escobar 1,2,3 , Rodrigo Madurga 3,4 , José María Castellano 2,3,5 , Santiago Ruiz de Aguiar 3,6 , Sara Velázquez 3,7,8 , Marina Bucar 3,9 , Sara Jimeno 1,2,3 , Paula Sol Ventura 3,10

ABSTRACT
The clinical impact of COVID-19 disease calls for the identification of routine variables to identify patients at increased risk of death. Current understanding of moderate-to-severe COVID-19 pathophysiology points toward an underlying cytokine release driving a hyperinflammatory and procoagulant state. In this scenario, white blood cells and platelets play a direct role as effectors of such inflammation and thrombotic response. We investigate whether hemogram-derived ratios such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio and the systemic immune-inflammation index may help to identify patients at risk of fatal outcomes. Activated platelets and neutrophils may be playing a decisive role during the thromboinflammatory phase of COVID-19 so, in addition, we introduce and validate a novel marker, the neutrophil-to-platelet ratio (NPR).

Two thousand and eighty-eight hospitalized patients with COVID-19 admitted at any of the hospitals of HM Hospitals group in Spain, from March 1 to June 10, 2020, were categorized according to the primary outcome of in-hospital death.

Baseline values, as well as the rate of increase of the four ratios analyzed were significantly higher at hospital admission in patients who died than in those who were discharged (p<0.0001). In multivariable logistic regression models, NLR (OR 1.05; 95% CI 1.02 to 1.08, p=0.00035) and NPR (OR 1.23; 95% CI 1.12 to 1.36, p<0.0001) were significantly and independently associated with in-hospital mortality. According to our results, hemogram-derived ratios obtained at hospital admission, as well as the rate of change during hospitalization, may easily detect, primarily using NLR and the novel NPR, patients with COVID-19 at high risk of in-hospital mortality.

INTRODUCTION
The current global pandemic of COVID-19 has posed a major threat to global public health. Despite the fact that the majority of patients are asymptomatic or present mild symptoms, due to the high proportion of people affected, the number of deaths has exceeded 1.4 million people worldwide as of December 2020. Given the rapid spread and profound clinical consequences of COVID-19, it is imperative to continuously improve and advance appropriate, scalable and efficient clinical diagnostic and therapeutic innovations.

In this context, several studies have attempted to establish a series of epidemiological, analytical and clinical risk factors in order to identify patients at risk of mechanical ventilation or death. These studies have included outcomes of severity, ICU transfer and factors most associated with in-hospital mortality.

Some of the variables that have shown significant correlation with poor outcomes include
several analytical parameters, male sex, older age, smoking status and the coexistence of comorbidities such as obesity, hypertension, diabetes, cardiovascular disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, hepatitis B infections and malignancy.1–4

The pathophysiology of severe COVID-19 appears to be closely related to a hyperinflammatory state and endothelial damage, therefore circulating biomarkers that can represent inflammation and immune status could potentially predict the clinical outcomes of patients with COVID-19.3–11

Based on these pathophysiological plausibility and clinical observations,3–5 several systematic inflammatory response markers have been evaluated and found to correlate with poor outcomes, including peripheral white blood cell (WBC) count, neutrophil-to-lymphocyte ratio (NLR), derived NLR ratio (neutrophil count divided by the result of WBC count minus neutrophil count), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio.4–12

NLR and PLR have been proposed as inflammatory markers in a variety of diseases, including COVID-19.1,3–8 NLR appears to be an indicator of endothelial dysfunction and an important predictor of cardiovascular mortality.16–17 Different publications have shown the use of PLR as an informative marker in acute inflammatory and prothrombotic states. PLR appears to be a better predictor of clinical outcomes in patients with systemic inflammation than isolated platelet or lymphocyte counts,3,5 but the relationship between PLR and mortality has been less explored. It has been postulated15 that PLR may reflect the degree of cytokine release, which might provide a useful indicator the clinical evolution of patients with COVID-19. Systemic immune-inflammation index (SII) has been recently proposed as a prognostic indicator in the follow-up of sepsis18 and in patients with cancer19 as an index defining the instability in the inflammatory response.

To date, few articles have been published investigating the relationship between the hemogram and all its inflammatory indices and the COVID-19.3,12–20

According to previous results12–20 and expanding on the current understanding of the pathophysiology of severe COVID-19, we hypothesized that specific hemogram-derived ratios at hospital admission and their respective rates of change during hospitalization may help identify patients at high risk of in-hospital mortality.

**MATERIALS AND METHODS**

A retrospective observational study was performed at HM Hospitals including 2453 hospitalized patients with COVID-19 due to confirmed or suspected infection by SARS-CoV-2 who were admitted to any of the 10 hospitals of the HM Hospitals group across different regions (including Madrid, Barcelona and Galicia) from March 1 to June 10, 2020. Clinical and laboratory data measurements were available up to and including June 24, 2020.

Diagnostic criteria set forth by the Spanish Ministry of Health changed during the study period, due to the dramatic pandemic situation with overwhelming numbers of admissions and shortage of PCR tests. For several weeks, the diagnosis of COVID-19 was based solely on clinical characteristics and radiological criteria.

Data from 2453 patients were collected. Patients aged under 18 years (n=5), missing laboratory data (n=216) or being transferred to other designated hospitals during hospitalization (n=144) were excluded from the analysis. Twenty-six patients died in the emergency room and 10 patients died during the first 24 hours after admission. These patients were excluded due to insufficient data for analysis. In total, of the 2453 patients screened for the current study, 2088 (85.1%) were included in the final analysis (online supplemental figure S5).

Infection by SARS-CoV-2 was confirmed by PCR in 1954 (93.6%) patients. The remaining 134 patients included presented clinical and/or radiological signs compatible with COVID-19, as per protocol.

Information from each patient was collected from the electronic health report system at hospital admission including demographic data, comorbidities, epidemiological characteristics and laboratory results and up to discharge of in-hospital death.

All patients were initially assessed in the emergency department where a blood sample was drawn. Laboratory assessments include complete blood count (including WBC count, leukocyte subtypes, hemoglobin count and platelet count), biochemical parameters (aspartate aminotransferase, alanine aminotransferase, creatinine; lactate dehydrogenase (LDH), C reactive protein (CRP), urea and glucose) and various blood coagulation tests (including D-dimer, prothrombin time and activated partial prothrombin time).

Three distinct ratios derived from routine hemogram parameters signal inflammation. These include NLR, which is the ratio between the count of neutrophils (×10⁹ cells/L) and the count of lymphocytes (×10⁹ cells/L), PLR is the ratio between the count of platelets (×10¹¹ cells/L) and the count of lymphocytes (×10⁹ cells/L) and the SII is defined as the counts of neutrophils (×10⁹ cells/L) multiplied by the counts of platelets (×10¹¹ cells/L) and divided by the count of lymphocytes (×10⁹ cells/L).

Additionally, we have investigated the utility of a novel parameter, the neutrophil-to-platelet ratio (NPR), in its capacity to identify patients at higher risk of COVID-19. NPR is the ratio between the count of neutrophils (×10⁹ cells/L) and the count of platelets (×10¹¹ cells/L), and may be useful in signaling a combination of hyperinflammatory response and microvascular occlusion that has been identified in moderate-to-severe COVID-19 cases.23–25

Baseline measurements as well as the rate of change (defined as the change of up to four consecutive results during hospital admission) of the different inflammation ratios were included for analysis. Based on these measurements, the rate of change was defined as the slope of the linear fit of the relative rates versus time from hospital entry in days. A rate of change higher than 10% per day was considered as positive, lower than −10% per day as negative and between −10% and 10% per day as null.

The primary outcome of the present study was to evaluate the use of hemogram-derived ratios as inflammation markers and prognostic indicators of in-hospital mortality in patients with moderate-to-severe COVID-19.

Continuous variables were summarized as median (IQR) and categorical variables as absolute frequency (relative frequency, %). Summary statistics were performed for the
Figure 1  Interactions and stratified analyses for neutrophil-to-lymphocyte ratio (NLR) (A) and for neutrophil-to-platelet ratio (NPR) (B) adjusted to model A (table 5) and conducted for age (<75 and >75 years), sex, cardiovascular disease (CD), diabetes mellitus (DM), oxygen saturation (<90% and >90%) (SatO2) and lactate dehydrogenase (LDH) and C reactive protein (CRP) both categorized through their respective median values.
whole cohort and grouping patients in survivors and non-survivors. Differences between those groups were evaluated using Mann-Whitney U test for quantitative variables and χ² test or Fisher’s exact test for categorical variables. Correlations between continuous variables were evaluated by Spearman’s rho test under rho equals 0 null hypothesis. Correlation plots between pairs of variables were obtained using the R package GGally. Variables with p value <0.2 for difference between survivors and non-survivors were selected for univariable logistic regression.

Bivariable logistic regression models were performed combining one of the inflammatory ratios, NLR, PLR, NPR or SH, with other variables. Those variables that changed the inflammatory ratios estimate by at least 10% when added to the model were considered to build the multivariable adjusted models. Model A included age, diastolic blood pressure, NLR rate of change >10% per day, creatinine, blood urea and glucose. Models B–D included previous model and oxygen saturation (>94, 90–94 or <90 %), LDH and CRP, respectively.

### Table 1: Baseline demographics and clinical characteristics (% and median value (IQR))

<table>
<thead>
<tr>
<th>Demographics characteristics</th>
<th>Total (n=2088)</th>
<th>Non-survivors (n=321)</th>
<th>Survivors (n=1767)</th>
<th>P value</th>
<th>Univariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>69 (57–80)</td>
<td>83 (75–89)</td>
<td>66 (55–77)</td>
<td>&lt;0.0001</td>
<td>1.09 (1.08 to 1.11)*</td>
</tr>
<tr>
<td>Male (%)</td>
<td>59.6%</td>
<td>66.4%</td>
<td>58.4%</td>
<td>0.0091</td>
<td>1.40 (1.10 to 1.81)</td>
</tr>
</tbody>
</table>

**Comorbidities**

<table>
<thead>
<tr>
<th></th>
<th>Total (n=2088)</th>
<th>Non-survivors (n=321)</th>
<th>Survivors (n=1767)</th>
<th>P value</th>
<th>Univariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>HT (%)</td>
<td>36.1%</td>
<td>45.5%</td>
<td>34.4%</td>
<td>0.00018</td>
<td>1.59 (1.25 to 2.02)</td>
</tr>
<tr>
<td>DM (%)</td>
<td>17.8%</td>
<td>23.7%</td>
<td>16.7%</td>
<td>0.0034</td>
<td>1.55 (1.16 to 2.05)</td>
</tr>
<tr>
<td>COPD (%)</td>
<td>5.6%</td>
<td>10%</td>
<td>4.8%</td>
<td>0.00036</td>
<td>2.19 (1.41 to 3.32)</td>
</tr>
<tr>
<td>CD (%)</td>
<td>11.1%</td>
<td>20.9%</td>
<td>9.3%</td>
<td>&lt;0.0001</td>
<td>2.58 (1.88 to 3.51)</td>
</tr>
</tbody>
</table>

**Clinical characteristics**

<table>
<thead>
<tr>
<th></th>
<th>Total (n=2088)</th>
<th>Non-survivors (n=321)</th>
<th>Survivors (n=1767)</th>
<th>P value</th>
<th>Univariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP min (mm Hg)</td>
<td>76 (67–84)</td>
<td>72 (62–80)</td>
<td>76 (68–85)</td>
<td>&lt;0.0001</td>
<td>0.98 (0.97 to 0.99)*</td>
</tr>
<tr>
<td>BP max (mm Hg)</td>
<td>131 (114–146)</td>
<td>131 (114–146)</td>
<td>131 (118–146)</td>
<td>0.35</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Laboratory findings at admission**

<table>
<thead>
<tr>
<th>Laboratory findings</th>
<th>Total (n=2088)</th>
<th>Non-survivors (n=321)</th>
<th>Survivors (n=1767)</th>
<th>P value</th>
<th>Univariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cells (10⁹/L)</td>
<td>6.6 (5.0–8.8)</td>
<td>8.4 (5.8–12.0)</td>
<td>6.4 (4.9–8.4)</td>
<td>&lt;0.0001</td>
<td>1.13 (1.10 to 1.16)*</td>
</tr>
<tr>
<td>Red blood cells (10⁹/L)</td>
<td>4.7 (4.3–5.1)</td>
<td>4.5 (4.0–4.9)</td>
<td>4.7 (4.3–5.1)</td>
<td>&lt;0.0001</td>
<td>0.67 (0.56 to 0.81)*</td>
</tr>
<tr>
<td>Neutrophils (10⁹/L)</td>
<td>4.7 (3.3–6.8)</td>
<td>7.0 (4.4–10.1)</td>
<td>4.5 (3.2–6.3)</td>
<td>&lt;0.0001</td>
<td>1.17 (1.14 to 1.21)*</td>
</tr>
<tr>
<td>Lymphocytes (10⁹/L)</td>
<td>1.1 (0.8–1.5)</td>
<td>0.8 (0.5–1.2)</td>
<td>1.1 (0.8–1.5)</td>
<td>&lt;0.0001</td>
<td>0.58 (0.46 to 0.73)*</td>
</tr>
<tr>
<td>Monocytes (10⁹/L)</td>
<td>0.5 (0.3–0.7)</td>
<td>0.5 (0.3–0.7)</td>
<td>0.5 (0.3–0.7)</td>
<td>0.14</td>
<td>NA</td>
</tr>
<tr>
<td>Platelets (10⁹/L)</td>
<td>207 (160–267)</td>
<td>186 (151–249)</td>
<td>210 (163–270)</td>
<td>&lt;0.0001</td>
<td>0.998 (0.996 to 0.999)*</td>
</tr>
</tbody>
</table>

**Baseline demographics and clinical characteristics (% and median value (IQR))**

<table>
<thead>
<tr>
<th>Laboratory findings</th>
<th>Total (n=2088)</th>
<th>Non-survivors (n=321)</th>
<th>Survivors (n=1767)</th>
<th>P value</th>
<th>Univariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>13.9 (12.6–15.0)</td>
<td>13.5 (11.9–14.8)</td>
<td>13.9 (12.8–15.0)</td>
<td>0.00034</td>
<td>0.88 (0.83 to 0.94)*</td>
</tr>
<tr>
<td>MCHC (g/dL)</td>
<td>33.7 (32.8–34.5)</td>
<td>33.2 (32.1–34.1)</td>
<td>33.7 (32.9–34.5)</td>
<td>&lt;0.0001</td>
<td>0.70 (0.64 to 0.76)*</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>88.2 (85.1–91.4)</td>
<td>90.3 (86.8–94.0)</td>
<td>87.9 (84.9–90.9)</td>
<td>&lt;0.0001</td>
<td>1.07 (1.05 to 1.10)*</td>
</tr>
<tr>
<td>MPV (fL)</td>
<td>10.3 (9.6–11.0)</td>
<td>10.5 (9.9–11.3)</td>
<td>10.2 (9.6–11.0)</td>
<td>&lt;0.0001</td>
<td>1.37 (1.22 to 1.54)*</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>31.6 (22.5–49.2)</td>
<td>37.7 (26.3–58.1)</td>
<td>30.6 (21.7–46.9)</td>
<td>&lt;0.0001</td>
<td>1.01 (1.00 to 1.01)*</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>25.8 (16.1–42.6)</td>
<td>22.3 (14.2–37.9)</td>
<td>26.0 (16.6–43.6)</td>
<td>0.0014</td>
<td>1.00 (0.99 to 1.00)</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.9 (0.7–1.1)</td>
<td>1.1 (0.9–1.6)</td>
<td>0.9 (0.7–1.0)</td>
<td>&lt;0.0001</td>
<td>4.28 (3.36 to 5.50)*</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>517 (394–673)</td>
<td>658 (509–935)</td>
<td>500 (383–639)</td>
<td>&lt;0.0001</td>
<td>1.02 (1.02 to 1.03)*</td>
</tr>
<tr>
<td>C reactive protein (mg/L)</td>
<td>64 (24–131)</td>
<td>120 (68–228)</td>
<td>55 (21–115)</td>
<td>&lt;0.0001</td>
<td>1.01 (1.01 to 1.01)*</td>
</tr>
<tr>
<td>Urea (mg/dL)</td>
<td>34.1 (26.0–49.0)</td>
<td>56.0 (42.3–92.0)</td>
<td>32.4 (24.7–44.4)</td>
<td>&lt;0.0001</td>
<td>1.03 (1.03 to 1.04)*</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>114 (101–136)</td>
<td>126 (110–163)</td>
<td>112 (99–132)</td>
<td>&lt;0.0001</td>
<td>1.01 (1.01 to 1.01)*</td>
</tr>
<tr>
<td>Partial thromboplastin time (s)</td>
<td>32 (30–35)</td>
<td>32 (30–36)</td>
<td>32 (30–35)</td>
<td>0.076</td>
<td>1.03 (1.01 to 1.04)*</td>
</tr>
<tr>
<td>D-dimer (mg/L)</td>
<td>0.7 (0.4–1.4)</td>
<td>1.3 (0.7–2.7)</td>
<td>0.7 (0.4–1.2)</td>
<td>&lt;0.0001</td>
<td>1.04 (1.02 to 1.06)*</td>
</tr>
<tr>
<td>Prothrombin time (s)</td>
<td>13.2 (12.3–14.5)</td>
<td>14.1 (12.8–16.1)</td>
<td>13.1 (12.3–14.2)</td>
<td>&lt;0.0001</td>
<td>1.01 (1.01 to 1.02)*</td>
</tr>
</tbody>
</table>

*The variable is continuous, the OR is for each increment in a unit. Non-survivors versus survivors.

BP, blood pressure; CD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HT, hypertension; NA, not available; SatO₂, oxygen saturation.
Interaction and stratified analyses were performed for each inflammatory ratio adjusted to model A and conducted for age (<75 and ≥75 years), sex, cardiovascular disease, diabetes mellitus, oxygen saturation (<90 and >90 %) and LDH and CRP both categorized through their respective median values (figure 1A,B, online supplemental figures S1C,D).

Statistical inference was performed using two-tailed test and with type I error rate of 0.05. All statistical analyses were done using R (V4.0.0).

RESULTS
Clinical, epidemiological and laboratory data for 2088 patients admitted to HM Hospitales group due to COVID-19 infection from March 1 to June 10, 2020, were included for analysis. Clinical characteristics are summarized in table 1 and laboratory results are presented in tables 2 and 3. The median age of patients was 69 (57–80) years and 59.6% were men.

Three hundred and twenty-one (15.3%) patients died. At the time of hospital admission, baseline clinical differences were observed between patients who died and those who did not, including age (83 (75–89) vs 66 (55–77), OR 1.09; 95% CI 1.08 to 1.11; p<0.0001), sex (66.4% vs 58.4% males, OR 1.4; 95% CI 1.10 to 1.81; p=0.0091) and SaO₂ (SaO₂ <90%–37.4% vs 10.9%, OR 6.7), p<0.0001) and SII (16.4 (7.5–31.5) vs 8.5 (4.7–15.5), p<0.0001) than those who were discharged (table 3).

Comorbidities were significantly more prevalent among patients who died, specifically hypertension (45.5% vs 34.4%, OR 1.59; 95% CI 1.25 to 2.02; p=0.00018), diabetes mellitus (23.7% vs 16.7%, OR 1.55; 95% CI 1.16 to 2.05; p=0.0034), chronic obstructive pulmonary disease (10% vs 4.8%, OR 2.19; 95% CI 1.41 to 3.32; p=0.00036) and previous cardiovascular disease (20.9% vs 9.3%, OR 2.58; 95% CI 1.88 to 3.51; p<0.0001) (table 1).

Patients who died presented significantly higher baseline values of NLR (8.7 (4.3–14.3) vs 3.8 (2.5–6.7), p<0.0001), PLR (2.4 (1.5–3.7) vs 1.9 (1.3–2.8), p<0.0001), NPR (3.5 (2.4–5.0) vs 2.1 (1.5–3.0), p<0.0001) and SII (16.4 (7.5–31.5) vs 8.5 (4.7–15.5), p<0.0001) than those who were discharged (table 3).

Independent mortality prediction ability was shown for each hemogram-derived ratio (receiver operating characteristic curves are shown in online supplemental figure S2 and optimal cut-off values are shown in table 4). Furthermore, these patients presented a significantly higher rate of ascension in the velocity of NLR (39.3% vs 17.3% OR 4.79; 95%CI 3.47 to 6.66, p<0.0001), PLR (36.1% vs 25.6% OR 3.05; 95%CI 2.24 to 4.17, p<0.0001), NPR (49.5% vs 41.1% OR 2.58; 95%CI 1.90 to 3.53, p<0.0001) and SII (42.4% vs 27.4% OR 3.68; 95%CI 2.64 to 5.21, p<0.0001) (table 3).

The results of multivariable logistic regression models assessing the relation of the different hemogram-derived ratios and mortality are shown in table 5. Model A adjusted the hemogram-derived ratios OR for age, diastolic blood pressure, positive NLR rate of change, creatinine, blood urea and glucose. This adjustment did not weaken the association between each ratio and mortality. However, a weak decrease in OR can be observed when oxygen saturation <90% was added to the adjustment variables and PLR lost its association with mortality as did SII in model D which included the addition of CRP to the adjustment variables. Conversely, NLR and NPR remained predictors of in-hospital mortality when adjusted for the more complex model D (table 5).

Stratified analysis showed that increasing values of NLR associates with mortality for both males (OR 1.09, p<0.001) and females (OR 1.07, p<0.001), age ≥75 years (OR 1.08, p<0.001) and age <75 years (OR 1.09, p<0.001) and LDH above median (>517 U/L) (OR 1.07, p<0.001).
p<0.001) and LDH below median (<517 U/L) (OR 1.12, p<0.001), with no significant interaction. Interaction with NLR was observed for presence of cardiovascular disease (OR 1.04, p=0.15) and absence of cardiovascular disease (OR 1.11, p<0.001) (p of interaction <0.001), for the presence of diabetes (OR 1.06, p=0.0077) and absence of diabetes (OR 1.09, p<0.001) (p of interaction <0.001) and a borderline significant interaction (p=0.05) was found for oxygen saturation >90% (OR 1.05, p=0.0027) and <90% (OR 1.11, p<0.001) (figure 1A).

Regarding stratified analysis for increasing values of NPR, interaction with NPR was observed for presence of diabetes (OR 1.15, p=0.049) and absence of diabetes (OR 1.40, p<0.001) (p for interaction=0.003) and for CRP >64 mg/L (median value) (OR 1.21, p<0.001) and CRP >64 mg/L (OR 1.65, p<0.001) (p for interaction=0.029). For the remaining variables, analyzed NPR did not show significant interaction with mortality independently of the stratification (figure 1B).

Interactions and stratified analyses for PLR and SII are shown in online supplemental figures S1C,D.

Correlation analysis between the four hemogram-derived ratios (online supplemental figure S3) shows that NLR correlated with all other hemogram-derived ratios independently from mortality (NLR vs PLR, r=0.7, p<0.001; NLR vs NPR, r=0.667, p<0.001; NLR vs SII, r=0.89, p<0.001). However, PLR is correlated with SII (r=0.814, p<0.001) but not with NPR (r=0.003, p=0.88). Finally, NPR and SII showed a significant but weak correlation (r=0.417, p<0.001).

Online supplemental figures S4A,B show the correlation analysis between NLR, NPR, PLR and SII and those variables that were significantly associated with mortality. As expected, the ratios were correlated with the hemogram parameters including neutrophils (NLR: r=0.744, p<0.001; NPR: r=0.720, p<0.001; SII: r=0.792, p<0.001) and lymphocytes (NLR: r=0.694, p<0.001; PLR: r=0.719, p<0.001; SII: r=0.493, p<0.001) or platelets (NPR: r=0.323, p<0.001; PLR: r=0.470, p<0.001; SII: r=0.517, p<0.001). All the hemogram-derived ratios were significantly but weakly correlated with most of the different laboratory and demographic variables but NLR and CRP (r=0.56, p<0.001), which was the only case with a correlation >0.5.

### DISCUSSION

At the time of analysis there had been, to the best of our knowledge, no reports on the potential use of various hemogram-derived ratios that signal inflammation and coagulation as prognostic markers of in-hospital mortality in COVID-19. Very recently, two studies including small cohorts have been published exploring the usefulness of known hemogram-derived ratios. One describes laboratory and radiological findings in a small group of patients and another compares blood inflammatory markers in SARS-CoV-2 virus infection to influenza A.

In most clinical care settings, the first encounter with patients with moderate-to-severe COVID-19 takes place in the emergency department, where it is routine clinical practice to carry out a full blood panel. According to our results, in predisposed patients with COVID-19, SARS-CoV-2 causes a hyperinflammatory/hypercoagulable response. This response can be measured, quantified and its evolution during admission may help identify patients at high risk of in-hospital mortality (tables 1 and 2). Importantly, some of these parameters may fall within their normal range at admission, hence the significance in the evolution for a prognostic use.

Several studies have reported laboratory characteristics of patients with severe COVID-19, and have found low lymphocytes, high leukocytes and high NLR, as well as lower percentages of monocytes, eosinophils and basophils. Following alveolar viral damage by SARS-CoV-2, the host’s inflammatory response to SARS-CoV-2 infection appears critical in clinical evolution of COVID-19 as a hyperinflammatory response has been identified in moderate-to-severe cases. Blood cell interactions are essential in the pathophysiology of inflammation, immune responses and hemostasis and endothelial cells may be playing an important role as a driver of inflammation mediating the release of cytokines. In this context, activated platelets and neutrophils play a determining role in microvascular occlusion during the thromboinflammatory phase of the disease and could be useful counts and have prognostic value in patients with severe COVID-19.

Our study emphasizes the utility of the total number of white cell, lymphocyte neutrophil or platelet recruited and the
utility of hemogram-derived ratios in evolution of hospitalized patient reflecting the complexity and heterogeneity of SARS-CoV-2 infection response.

According to our results, consistent with previous data, NLR is associated with in-hospital mortality as it is higher at baseline hospital admission and maintains significance after multivariable adjustment.

We observed that patients who died presented significantly higher PLR and SII at admission compared with patients who survived, but they did not maintain significance after more complex model of multivariable adjustment.

The modulatory interaction between neutrophils and platelets has been previously described. We included the blood cell proportion NPR based on the biological plausibility of higher total neutrophils count and lower total platelets count observed among the most severe COVID-19 cases compared with more mild ones. Interestingly, NPR levels were significantly associated with mortality and its association remained significant even after multivariable adjustment. This represents a novel finding which merits further investigation.

Overall, the use of four hemogram-derived ratios from routine blood counts may help identify severe cases of COVID-19 at higher risk of in-hospital mortality. Of these, NLR and NPR appear to be independently associated with mortality in multivariable adjusted models. This relationship would be explained by the capacity of these measures to signal cell activation, endothelial dysfunction following a hyperinflammatory state along with other, more established markers including LDH, CRP and markers of coagulation.

The velocity of increase in the value of these ratios has shown to be a useful marker of severity and associates with mortality in the current study. Undoubtedly, these rates of change could be affected by COVID-19 and by treatments applied, but we hypothesize that some of these rates could be a parameter of value in the surveillance of patients without additional risk factors that support a possible benefit of changing the therapeutic decision.

We are aware the current study presents several limitations. COVID-19 was not confirmed in all patients of both groups, but during the period of the study, as a consequence of the changes in the diagnostic protocol by the Spanish Ministry of Health due to the dramatic pandemic situation, and following instructions in the diagnostic protocols, the diagnosis of COVID-19 in some cases was based solely on clinical characteristics and radiological criteria. We realize that the change rates could be modified by concomitants treatment such as corticosteroids or tocilizumab, so the rates and their utility have to be proven in more cohorts but we found significant differences of blood cell proportions at hospital admission prior to any treatment. Finally, the in-hospital mortality shown in our results does not correspond to the overall mortality as during first wave, population’s fear led to late hospital care, which resulted in a high percentage of deaths in the first 24 hours of admission and those patients were not included in the analysis even though they had blood tests, since the research team understood that the deterioration of the patient had taken place several days earlier and therefore the analytical control in the emergency room could bias the analysis. On the other hand, patients in an unfavorable social situation or with longer expected admissions discharged to medicized hotels and therefore with unexpected deaths, were not taken into account since, although they presumably did not die, there was no reliable proof of this.

CONCLUSIONS
Hemogram-derived ratios at hospital admission and rates of ascent during first days of hospital stay have shown their usefulness as prognostic markers of inflammation in patients who ultimately died, especially NLR and novelty NPR.

Hemogram is easily measurable, available, cost-effective and reliable test that could be very useful in establishing the risk of mortality at hospital admission and guiding therapeutic decisions in patients with COVID-19. In this sense, the hemogram is a tool within the reach of all hospitals and doctors who do not have the technical and material means to carry out complex immunological studies, which often produce late results. The analysis of the blood cells proportions obtained from the hemogram would provide much more information than could be extracted a priori by evaluating the parameters in isolation. We now know that it is crucial to initiate early anti-inflammatory treatment when the patient deteriorates and the hemogram could be an indicator of that signal that could indicate which patients could potentially benefit from earlier anti-inflammatory therapy. Further comprehensive studies are needed to determine how useful are these blood tests and future prognostic scores will demonstrate their usefulness in guiding treatment decisions.

Author affiliations
1Pediatrics Department, HM Hospitales, Madrid, Spain
2Faculty of Medicine, Universidad San Pablo CEU, Madrid, Spain
3Fundación de Investigación, HM Hospitales, Madrid, Spain
4Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Comunidad de Madrid, Spain
5Cardiology Department, Hospital Universitario HM Montepríncipe, HM Hospitales, Madrid, Spain
6Medical Management, HM Hospitales, Madrid, Spain
7Anaesthesia Department, HM Hospitales, Madrid, Spain
8Anaesthesia Department, Hospital Universitario Santa Cristina, Madrid, Spain
9Internal Medicine Department, HM Hospitales, Madrid, Spain
10Pediatrics Department Hospital Universitario HM Nens, HM Hospitales, Barcelona, Madrid, Spain

Twitter Alejandro López-Escobar @alopez_escobar


Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by the HM Hospitales ethics committee on March 25, 2020 (approval number 20.03.1573-GHM).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages),
and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD
Alejandro López-Escobar http://orcid.org/0000-0002-9052-1429

REFERENCES
COVID-19 patients with clinical outcomes admitted to one of the hospitals of HM Hospitales group between March 1 and June 10 2020 (n = 2453)

365 patients were excluded:
• Transferred to other designated hospitals, n = 144 (39.4%).
• Missing baseline data, n = 216 (59.2%).
• Under 18 years old, n = 5 (1.4%).

Patients included in the analysis (n = 2088).

Supplementary Figure S5. Patients Flowchart
Supplementary Figure S1C. Interactions and stratified analyses for PLR (platelet-lymphocyte ratio) adjusted to model A (Table 5) and conducted for age (< 75 and > 75 years), sex, cardiovascular disease (CD), diabetes mellitus (DM), oxygen saturation (< 90 and > 90 %) (SatO₂), and lactate dehydrogenase (LDH) and C-reactive protein (CRP) both categorized through their respective median values.
Supplementary Figure S1D. Interactions and stratified analyses for SII (systemic immune-inflammation index) adjusted to model A (Table 5) and conducted for age (< 75 and > 75 years), sex, cardiovascular disease (CD), diabetes mellitus (DM), oxygen saturation (< 90 and > 90 %) (SatO₂), and lactate dehydrogenase (LDH) and C-reactive protein (CRP) both categorized through their respective median values.
Supplementary Figure S2. ROC curves for the different hemogram-derived ratios and their respective areas under the curves (AUC).
Supplementary Figure S3. Correlation analysis between the four hemogram ratios. Abbreviations: NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; NPR, neutrophil-platelet ratio; SII, systemic immune-inflammation index.
Supplementary Figure S4A. Correlation analysis between NLR and NPR and those variables that were significantly associated with mortality. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; NPR, neutrophil-to-platelet ratio; BP min, minimum blood pressure; HGB, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; WBC, white blood cells; RBC, red blood cells; NEU, neutrophils; LYM, lymphocytes; EOS, eosinophils; PLAT, platelets; AST, aspartate aminotransferase; CREA, creatinine; LDH, lactate dehydrogenase; CRP, C-reactive protein; DD, D-dimer; PT, prothrombin time; GLU, glucose.
Supplementary Figure S4B. Correlation analysis between PLR and SII and those variables that were significantly associated with mortality. Abbreviations: PLR (platelet-to-lymphocyte ratio); SII (systemic immune-inflammation index); BP min (minimum blood pressure), HGB (mean corpuscular hemoglobin); MCHC (mean corpuscular hemoglobin concentration); MCV (mean corpuscular volume); MPV (mean platelet volume); WBC (white blood cells); RBC (red blood cells); NEU (neutrophils); LYM (lymphocytes); EOS (eosinophils); PLAT (platelets); AST (aspartate aminotransferase); CREA (creatinine); LDH (lactate dehydrogenase); CRP (C-reactive protein); DD (D-dimer); PT (prothrombin time); GLU (glucose).